Pyrr, I just want to say that I've learned so much about how to research biotechs from reading your lengthy, detailed pieces, as well as the work of others. I can't tell you how much I appreciate every word you've written. A year and a half ago when I decided to invest in biotechs, I didn't know there were different types of FDA trials, such as AA and fast track and orphan designation; I didn't know that some endpoints were acceptable in some types of trials and not in others; I didn't understand how important manufacturing was to getting approval in new drugs; I didn't understand statistics and how much it factored into clinical trial designs. I also didn't understand the lengths to which Wall Streets characters would go to spread disinformation to make money, without regard to the effect it could have on the development of groundbreaking treatments. You and others have been kind enough to share your knowledge and it's helped me and, I'm sure, many, many others to do our own due diligence.
I happen to enjoy learning, reading and researching and I use this message board as a way to find clues, websites and information that I can research myself so that I can make my own determinations. I believe the best way to invest in biotechs is by reading the scientific papers and clinical trials, etc., but I've learned that there are good times to invest and bad times to invest. I particularly appreciate the link you just sent on fast track drugs and the FDA. It really does spell out why NWBO's endpoints will work toward FDA approval, and dispels AF's argument.
So, I just want to assure you and others who are not posting as often - perhaps because of the increased volume of writings by naysayers - that for every one negative comment made by a poster, there are undoubtedly dozens of us who don't post as often, but greatly appreciate the knowledge we've gained from following your writings.
And by the way, I still think that NWBO's upcoming annual report, due out by April 7th according to zack's small cap, will help move the stock if we have our first line for income.
The catalysts are lining up.
